This segment explores how emerging data on oral selective estrogen receptor degraders are being applied in clinical practice for hormone receptor–positive, HER2-negative metastatic breast cancer.
This segment introduces the evolving treatment landscape in hormone receptor–positive, HER2-negative metastatic breast cancer, with a focus on the growing clinical relevance of ESR1 mutations.
A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.
Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.
Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.
Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.
A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.
A medical expert navigates toxicity management in patients being treated with ribociclib.
Dr. Rugo details her management strategy in regards to GI toxicities.
Dr. Dempsey details how different types of endocrine therapies have impacted toxicities within her patients.
A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.
